Immune oncology central to Merck KGaA's pharma growth hopes
This article was originally published in Scrip
Executive Summary
Merck KGaA is hoping to climb the pharma ranks in the next few years through the development of its pipeline and the overall makeover of the business. Comments by the chair of the firm's executive board, Dr Karl-Ludwig Kley, during the firm's annual financial results conference, highlight the importance of immune oncology in its healthcare business growth hopes.